Top

Irish Journal of Medical Science (1971 -)

Published in:

01-03-2011 | Original Article

The utility of ^99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism

Authors: N. Glynn, N. Lynn, C. Donagh, R. K. Crowley, D. Smith, C. J. Thompson, A. D. K. Hill, F. Keeling, A. Agha

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2011

Abstract

Background

There are conflicting data in the literature about the sensitivity of sestamibi scintigraphy in parathyroid tumour localisation in primary hyperparathyroidism (PHPT).

Aim

We aimed to evaluate the overall sensitivity of this modality in parathyroid tumour localisation and to determine clinical and biochemical factors which influence sensitivity of this method.

Methods

We performed a retrospective review of 57 patients with a biochemical diagnosis of PHPT who had sestamibi scintigraphy performed.

Results

The sensitivity of sestamibi scanning was 56% in whole group and 63% in those without nodular thyroid disease. Among the patients with confirmed single gland disease (biochemical cure after surgical removal of a single adenoma), sensitivity was 71%. A positive scan was associated with younger age, greater adenoma weight and higher pre-operative serum calcium. Concordance between the sestamibi and neck ultrasonography was 92% accurate in pre-operative tumour localisation.

Conclusion

Sestamibi scintigraphy was more likely to be positive in younger patients without nodular thyroid disease who have larger parathyroid adenomas with more severe hyperparathyroidism.

Heath H 3rd, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302(4):189–193CrossRefPubMed

Russell CF, Edis AJ (1982) Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg 69(5):244–247CrossRefPubMed

Bilezikian JP, Silverberg SJ (2000) Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord 1(4):237–245CrossRefPubMed

Kaplan EL, Yashiro T, Salti G (1992) Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. Ann Surg 215(4):300–317CrossRefPubMed

Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH (2009) Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94(2):366–372CrossRefPubMed

Gotthardt M, Lohmann B, Behr TM et al (2004) Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature. World J Surg 28(1):100–107CrossRefPubMed

Taillefer R, Boucher Y, Potvin C, Lambert R (1992) Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 33(10):1801–1807PubMed

Allendorf J, Kim L, Chabot J, DiGiorgi M, Spanknebel K, LoGerfo P (2003) The impact of sestamibi scanning on the outcome of parathyroid surgery. J Clin Endocrinol Metab 88(7):3015–3018CrossRefPubMed

Hindie E, Melliere D, Perlemuter L, Jeanguillaume C, Galle P (1997) Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Radiology 204(1):221–228PubMed

10.

Moure D, Larranaga E, Dominguez-Gadea L et al (2008) 99MTc-sestamibi as sole technique in selection of primary hyperparathyroidism patients for unilateral neck exploration. Surgery 144(3):454–459CrossRefPubMed

11.

Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE (1989) 99Tcm sestamibi—a new agent for parathyroid imaging. Nucl Med Commun 10(11):791–794CrossRefPubMed

12.

Civelek AC, Ozalp E, Donovan P, Udelsman R (2002) Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery 131(2):149–157CrossRefPubMed

13.

Pappu S, Donovan P, Cheng D, Udelsman R (2005) Sestamibi scans are not all created equally. Arch Surg 140(4):383–386CrossRefPubMed

14.

Thomas DL, Bartel T, Menda Y, Howe J, Graham MM, Juweid ME (2009) Single photon emission computed tomography (SPECT) should be routinely performed for the detection of parathyroid abnormalities utilizing technetium-99m sestamibi parathyroid scintigraphy. Clin Nucl Med 34(10):651–655CrossRefPubMed

15.

Hindie E, Melliere D, Jeanguillaume C, Perlemuter L, Chehade F, Galle P (1998) Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. J Nucl Med 39(6):1100–1105PubMed

16.

Biertho LD, Kim C, Wu HS, Unger P, Inabnet WB (2004) Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism. J Am Coll Surg 199(2):229–233CrossRefPubMed

17.

Bandeira FA, Oliveira RI, Griz LH, Caldas G, Bandeira C (2008) Differences in accuracy of 99mTc-sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol 36(1):30–35CrossRefPubMed

18.

Tublin ME, Pryma DA, Yim JH et al (2009) Localization of parathyroid adenomas by sonography and technetium Tc 99m sestamibi single-photon emission computed tomography before minimally invasive parathyroidectomy: are both studies really needed? J Ultrasound Med 28(2):183–190PubMed

19.

Gotway MB, Reddy GP, Webb WR, Morita ET, Clark OH, Higgins CB (2001) Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 218(3):783–790PubMed

Title: The utility of 99mTc-sestamibi scintigraphy in the localisation of parathyroid adenomas in primary hyperparathyroidism
Authors: N. Glynn
N. Lynn
C. Donagh
R. K. Crowley
D. Smith
C. J. Thompson
A. D. K. Hill
F. Keeling
A. Agha
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Irish Journal of Medical Science (1971 -) / Issue 1/2011
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-010-0641-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Brachial neuritis masquerading as acute coronary syndrome

The use of laryngeal mask airway for surgical tracheotomy in a neonate with Pierre Robin syndrome: a case report

Handover rounds in Irish hospitals

Serotonin syndrome in an orthopaedic patient secondary to linezolid therapy for MRSA infection

Readability level of patient information leaflets for older people

Factors affecting return to driving post-stroke

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials